Compare QTTB & ASPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QTTB | ASPN |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | RETAIL: Building Materials |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 450.1M | 363.8M |
| IPO Year | 2018 | 2011 |
| Metric | QTTB | ASPN |
|---|---|---|
| Price | $15.60 | $4.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $13.00 | $4.25 |
| AVG Volume (30 Days) | 420.5K | ★ 1.7M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 136.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $53,737,000.00 | ★ $271,103,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $50.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.62 | $2.30 |
| 52 Week High | $23.57 | $9.35 |
| Indicator | QTTB | ASPN |
|---|---|---|
| Relative Strength Index (RSI) | 53.16 | 43.85 |
| Support Level | $14.44 | $2.93 |
| Resistance Level | $16.78 | $5.48 |
| Average True Range (ATR) | 0.87 | 0.45 |
| MACD | -0.08 | -0.08 |
| Stochastic Oscillator | 43.57 | 5.19 |
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
Aspen Aerogels Inc is an aerogel technology company that designs, develops, and manufactures high-performance aerogel insulation used in the energy industrial and sustainable insulation markets. The company also conducts research and development related to aerogel technology, supported by funding from several agencies of the United States of America government and other institutions in the form of research and development contracts. It is engaged in two operating segment Energy Industrial and Thermal Barrier. Geographically, it operates in the U.S. and also has a presence in other International countries. It generates the majority of its revenue from the Thermal Barrier segment and the United States market. Some of its products include Pyrogel XTE, Cryogel Z, Spaceloft Subsea, and others.